| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
PI4KIII beta inhibitor 3 targets phosphatidylinositol 4-kinase III beta (PI4KIIIβ), a lipid kinase involved in the synthesis of phosphatidylinositol 4-phosphate (PI4P). It is a highly potent inhibitor with an IC50 of 5.7 nM. Inhibition of PI4KIIIβ impairs viral replication and tumor cell proliferation.
|
|---|---|
| ln Vitro |
PI4KIII beta inhibitor 3 is a PI4KIII inhibitor that was taken out of WO/2013034738 A1 patent. The IC50 value of formula 3's substance is 5.7 nM. In a mixed lymphocyte reaction (MLR) assay, PI4KIII beta inhibitor 3 exhibits strong immunosuppressive activity with an IC50 value of 3 nM. PI4KIII beta inhibitor 3 has an IC50 value of less than 1 nM for both IL2 and IFNγ secretion inhibition. Thus, in terms of blocking the release of IL2 and IFNγ, PI4KIII beta inhibitor 3 is just as efficient as conventional immunosuppressants like cyclosporin A. IFNy and IL-2 are released by cyclosporin A, with IC50 values of less than 1 nM and 2 nM, respectively [1].
In vitro, PI4KIII beta inhibitor 3 inhibits IL2 and IFNγ secretion with IC50 values of less than 1 nM. The compound demonstrates potent inhibition of PI4KIIIβ enzymatic activity with an IC50 of 5.7 nM. It shows antiviral and anticancer potential by impairing viral replication and tumor cell proliferation. |
| ln Vivo |
In an arthritis prevention model, PI4KIII beta inhibitor 3 (40 mg/kg daily, n = 12) reduces the severity of symptoms and delays the onset of arthritis symptoms when compared to vehicle control (MC 1%, n = 12). In a mouse model of collagen-induced arthritis, anti-CII IgG titers and histological scores are decreased by PI4KIII beta inhibitor 3. In three out of six grafts per group, oral administration of PI4KIII beta inhibitor 3 led to a prolonged graft survival at day thirty. Up to 60 days after treatment was stopped, some grafts persisted in beating, indicating the possibility that graft tolerance was induced. Animals receiving functional grafts at day 60 were challenged with a second graft from the same donor strain or from a different source in order to evaluate the procedural tolerance phenotype. There is no medical intervention. While a second graft from the same donor strain remained functional for over 90 days (n=2), the second graft from a third party was rejected by day 8 (n=2) [1].
In vivo, PI4KIII beta inhibitor 3 has been evaluated in preclinical models for antiviral and anticancer activity. As a PI4KIIIβ inhibitor, it impairs lipid signaling pathways essential for viral replication and tumor cell proliferation. |
| Enzyme Assay |
For enzyme inhibition assays, recombinant PI4KIIIβ enzyme is incubated with phosphatidylinositol and ATP in the presence of varying concentrations of PI4KIII beta inhibitor 3. The production of phosphatidylinositol 4-phosphate (PI4P) is measured using radioactive or HTRF-based assays. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays utilize cell lines dependent on PI4KIIIβ activity for proliferation or viral replication. Cells are treated with PI4KIII beta inhibitor 3 at various concentrations, and cell viability or viral replication is assessed. Cytokine secretion (IL2, IFNγ) may be measured by ELISA.
|
| Animal Protocol |
In vivo studies are conducted in animal models of viral infection or cancer. PI4KIII beta inhibitor 3 is administered via appropriate routes, and endpoints include viral load, tumor volume, and survival. The compound's efficacy in impairing viral replication and tumor cell proliferation is evaluated.
|
| ADME/Pharmacokinetics |
PI4KIII beta inhibitor 3 (molecular weight 446.53, formula C22H22N8OS) is a small-molecule lipid kinase inhibitor. The compound is primarily used as a research tool to study lipid signaling, Golgi function, and potential therapeutic targeting of PI4KIIIβ in disease models.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of PI4KIII beta inhibitor 3 have been limited, as the compound is primarily used as a research tool. No significant toxicity has been reported in the available literature. The compound's safety profile supports its use for studying PI4KIIIβ function.
|
| References | |
| Additional Infomation |
PI4KIII beta inhibitor 3 is a highly potent PI4KIIIβ inhibitor identified from WO/2013034738 A1. Its mechanism involves inhibition of PI4KIIIβ, a lipid kinase that synthesizes PI4P, a key regulator of Golgi function and lipid signaling. The compound shows antiviral and anticancer potential by impairing viral replication and tumor cell proliferation. It is primarily used as a research tool for studying lipid signaling and PI4KIIIβ biology.
|
| Molecular Formula |
C22H22N8OS
|
|---|---|
| Molecular Weight |
446.52808
|
| Exact Mass |
446.164
|
| CAS # |
1245319-54-3
|
| PubChem CID |
46916382
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.05
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
32
|
| Complexity |
639
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UWTRKIJAGTTXNM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H22N8OS/c1-14-4-6-16(7-5-14)25-22(31)30-11-9-29(10-12-30)18-17-20(28-21(23)27-18)32-19(26-17)15-3-2-8-24-13-15/h2-8,13H,9-12H2,1H3,(H,25,31)(H2,23,27,28)
|
| Chemical Name |
4-(5-amino-2-pyridin-3-yl-[1,3]thiazolo[5,4-d]pyrimidin-7-yl)-N-(4-methylphenyl)piperazine-1-carboxamide
|
| Synonyms |
PI4KIII beta inhibitor 3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20 mg/mL (~44.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2395 mL | 11.1975 mL | 22.3949 mL | |
| 5 mM | 0.4479 mL | 2.2395 mL | 4.4790 mL | |
| 10 mM | 0.2239 mL | 1.1197 mL | 2.2395 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA